Systemic reactions generally were mild and were slightly more likely among those receiving both vaccines compared with the COVID-19 mRNA booster alone.
Fourth COVID-19 vaccine dose safe for immunocompromised
Jul 18, 2022
Local and systemic reactions were reported less frequently after the fourth dose versus dose 3 of the primary vaccination series.
‘Be vigilant’ in face of OSHA scrutiny related to COVID-19, attorney advises
By
Kathleen Steele Gaivin
Jun 27, 2022
Skilled nursing facility and senior living community operators “should continue to be vigilant” in their COVID-19 mitigation measures even though the Occupational Safety and Health Administration’s...
Testimony: OSHA must take introspective look to ensure worker safety in future health crises
By
Kimberly Bonvissuto
May 26, 2022
The federal agency charged with protecting workplace safety needs to take a hard look at itself to more effectively ensure worker safety and health during a future crisis, according to testimony during...
Almost 30 percent of COVID-19 patients develop ‘long COVID’
May 02, 2022
Factors independently associated with PASC include hospitalization for COVID-19, having diabetes and higher body mass index.
Workplace ‘major driver’ of COVID infections in long-term care staff: study
By
Ron Rajecki
Apr 18, 2022
The workplace is a “major driver” of COVID-19 infections among long-term care and other healthcare workers, according to the results of a new study published in the American Journal of Infection Control....
Healthcare personnel more likely to be exposed to COVID-19 at work
Apr 14, 2022
HCP cases were more likely to report healthcare exposures and were less likely to report household/community exposures.
Fourth dose of BNT162b2 offers protection against severe COVID-19
Apr 08, 2022
Protection against COVID-19 did not wane in six weeks after receipt of fourth dose of the Pfizer–BioNTech vaccine; protection against the infection waned.
Effectiveness of Ad26.COV2.S vaccine stable for six months
Mar 22, 2022
A single dose of the Johnson & Johnson vaccine was 74% and 81% effective for preventing COVID-19 infection and hospitalizations, respectively, in the U.S. before and during delta variant surge.
Survival high with ECMO for selected severe COVID-19 patients
Mar 10, 2022
Of 30 patients, 90% survived to discharge; survival was 86.7% at a median follow-up of 10.8 months since ECMO cannulation.